REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.
Kucukcelebi S, van 't Land FR, van der Burg SH, Eskens FALM, Homs MYV, Willemsen M, Onrust-van Schoonhoven A, Rozendaal NEM, Fellah A, Vadgama D, Moskie M, Bezemer K, Doukas M, van Eijck CWF, Stadhouders R, de Vos-Geelen J, van Diepen AE, Enninga I, Meijer R, Ambarkhane SV, Ellmark P, Aerts JGJV, Groeneveldt C, van Eijck CHJ.
Kucukcelebi S, et al. Among authors: ellmark p.
Nat Commun. 2025 Nov 28;16(1):10609. doi: 10.1038/s41467-025-66092-1.
Nat Commun. 2025.
PMID: 41315287
Free PMC article.
Clinical Trial.